Discover
NERV
Minerva Neurosciences, Inc.
5.15
2 x 3.90
2 x 6.92
bid
ask
-
0.40
7.21%
2 @ 04:00 PM
5.15 +0.00 (0.00%)
| Ytd | 28.11% | |
| 1y | 208.38% |
5.13
day range
5.55
1.59
52 week range
12.46
| Open | 5.55 | Prev Close | 5.55 | Low | 5.13 | High | 5.55 | Mkt Cap | 239.93M |
| Vol | 123.62K | Avg Vol | 227.30K | EPS | -37.03 | P/E | N/A | Forward P/E | -0.79 |
| Beta | 0.17 | Short Ratio | 0.41 | Inst. Own | 30.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 5.31 | 200-d Avg | 4.77 | 1yr Est | 5.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-05 | 2024-09 | -1.01 | 2.97 | 3.98 | 394.06% |
| 2024-08-06 | 2024-06 | -0.97 | -1.09 | -0.12 | -12.37% |
| 2024-05-01 | 2024-03 | -1.2 | -1.13 | 0.07 | 5.83% |
| 2024-02-22 | 2023-12 | -0.88 | -1.19 | -0.31 | -35.23% |
| 2023-11-07 | 2023-09 | -0.77 | -1.03 | -0.26 | -33.77% |
| 2023-08-01 | 2023-06 | -0.44 | -1.12 | -0.68 | -154.55% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-06 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-08-07 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-05-02 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-02-27 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2023-08-02 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2023-05-16 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
Profile
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-04-30 | AHLHOLM FREDERICK W | Chief Financial Officer | 17.52K | Sale |
| 2023-05-01 | LUTHRINGER REMY | Chief Executive Officer | 184.82K | Sale |
| 2023-04-30 | RACE GEOFFREY | President | 51.32K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Federated Hermes, Inc. | 1.35M | 2.86M | 19.32% |
| 2024-09-29 | Vanguard Group Inc | 252.06K | 534.37K | 3.60% |
| 2024-09-29 | Renaissance Technologies, LLC | 157.20K | 333.26K | 2.25% |
| 2024-09-29 | O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 107.26K | 227.38K | 1.53% |
| 2024-09-29 | Blackrock Inc. | 72.67K | 154.06K | 1.04% |
| 2024-09-29 | Geode Capital Management, LLC | 56.46K | 119.69K | 0.81% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Federated Hermes Kaufmann Fund | 833.00K | 1.77M | 11.91% |
| 2024-07-30 | Federated Hermes Kaufmann Small Cap Fund | 696.15K | 1.48M | 9.95% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 175.81K | 372.71K | 2.51% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 74.26K | 157.42K | 1.06% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 30.07K | 63.75K | 0.43% |
| 2024-09-29 | Federated Hermes Kaufmann Fund II | 17.23K | 36.52K | 0.25% |
Split
| Split | Date |
|---|---|
| 1 : 8 | 2022-06-21 |